Clinical utility and adverse effects of amiodarone therapy

AACN Advanced Critical Care

Volumn 21, Issue 4, 2010, Pages 333-338

  Roberts, Melissa ^a  

^a Department of Pharmaceutical Care Services   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT;

ACUTE LUNG INJURY; ARTICLE; CHEMICALLY INDUCED DISORDER; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; RISK FACTOR;

ACUTE LUNG INJURY; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; HUMANS; RISK FACTORS; TACHYCARDIA, VENTRICULAR; VENTRICULAR FIBRILLATION;

EID: 78649274772     PISSN: 15597768     EISSN: 15597768     Source Type: Journal    
DOI: 10.1097/NCI.0b013e3181ef86fe     Document Type: Article

References (24)

1. Babatin M, Lee SS, Pollak P T. Amiodarone hepatotoxicity. Curr Vasc Pharmacol. 2008;6(3):228-236.
2. Amiodarone [package insert]. Princeton, NJ: Zydus Pharmaceuticals USA Inc; 2009.
3. Neff M. Practice guideline briefs. Am Fam Physician. 2005;71(7):1433- 1434.
4. Haffagee CI. Clinical pharmacokinetics of amiodarone. Clin Cardiol. 1987;10(7) (suppl 1): I6-I9.
5. Chow MS. Intravenous amiodarone: pharmacology, pharmacokinetics, and clinical use. Ann Pharmacother. 1996;30(6):637-643.
6. Sanoski CA. Atrial and ventricular arrhythmias: evolving practices. In: Richardson M, Chant C, Cheng JWM, Chessman KH, Hume AL, Hutchison LC, eds. Pharmacotherapy Self-Assessment Program: Book 1: Cardiology. 7th ed. Lenexa, KS: American College of Clinical Pharmacy; 2010:125-152.
7. Creswell LL, Schuessler RB, Rosenbloom M, Cox JL. Hazards of postoperative atrial arrhythmias. Ann Thorac Surg. 1993;56(3):539-549.
8. Crystal E, Garfinkle MS, Connolly SS, Ginger T T, Sleik K, Yusuf SS. Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery. Cochrane Database Syst Rev. 2004; (4): CD003611.
9. Mitchell LB, Exner DV, Wyse DG, et al. Prophylactic oral amiodarone for the prevention of arrhythmias that begin early after revascularization, valve replacement, or repair: PAPABEAR: a randomized controlled trial. JAMA. 2005;294(24):3093-3100.
10. Fuster V, Rydén LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. J Am Coll Cardiol. 2001;38(4):1231-1266.
11. Cahoon W, Flattery M P, Hess ML. Amiodarone: development, clinical indications, and safety. Prog Cardiovasc Nurs. 2007;22(3):173-176.
12. Medscape. http://img.medscape.com/fullsize/migrated/577/475/euro577475. tab1.gif. Accessed March 26, 2010.
13. Carlsson J, Miketic S, Windeler J, et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the strategies of treatment of atrial fibrillation (STAF) study. J Am Coll Cardiol. 2003;41:1690-1696.
14. Hagens VE, Ranchor AV, Van Sonderen E, et al. Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the rate control versus electrical cardioversion (RACE) study. J Am Coll Cardiol. 2004;43:241-247.
15. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation-Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet. 2000;356:1789-1794.
16. Opolski G, Torbicki A, Kosior DA, et al. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish how to treat chronic atrial fibrillation (HOT CAFE) study. Chest. 2004;126:476-486.
17. Wyse DG, Waldo AL, DiMarco J P, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347(23):1825-1833.
18. Newman CM, Price A, Davies DW, Gray TA, Weetman A P. Amiodarone and the thyroid: a practical guide to the management of thyroid dysfunction induced by amiodarone therapy. Heart. 1998;79:121-127.
19. Gonzalez P, Otero MJ, Barrueco M, Dominguez-Gil A. Amiodarone-induced skin pigmentation and pulmonary fibrosis. Hosp Pharm. 2002;37(6):615-618.
20. Martin WJ, Rosenow EC. Amiodarone pulmonary toxicity. Recognition and pathogenesis (part 2). Chest. 1988;93(6):1242-1248.
21. Burns KE, Piliotis E, Garcia BM, Ferguson KA. Amiodarone pulmonary, neuromuscular, and ophthalmological toxicity. Can Respir J. 2000;7(2):193-197.
22. Santaella RM, Fraunfelder FW. Ocular adverse effects associated with systemic medications. Drugs. 2007;67(1):84-85.
23. Martino E, Bartalena L, Bogazzi F, Braverman LE. The effects of amiodarone on the thyroid. Endocr Rev. 2001;22(2):240-254.
24. Delage C, Lagacé R, Huard J. Pseudocyanotic pigmentation of the skin induced by amiodarone: a light and electron microscopic study. Can Med Assoc J. 1975;112(10):1205-1208.